Titel
stringlengths 11
40
| Kapitelnummer
stringlengths 1
6
| Inhalt
stringlengths 114
4.85k
| Seite
stringlengths 7
11
| Quelle
stringclasses 1
value |
|---|---|---|---|---|
Purpose of medical device classification
|
1
|
The classification of medical devices in use by the EU medical device legislation is a risk-based system taking into account the vulnerability of
the human body and the potential risks associated with the devices. This approach uses a set of criteria that can be combined in various ways
in order to determine classification, e.g. duration of contact with the body, degree of invasiveness, local vs. systemic effect, potential toxicity,
the part of the body affected by the use of the device and if the device depends on a source of energy. The criteria can then be applied to a
vast range of different medical devices and technologies. These are referred to as the ‘classification rules’ and are set out in Annex VIII of
Regulation (EU) 2017/745 on medical devices (MDR). They correspond, to a large extent, to the classification rules established by the
International Medical Device Regulators Forum (IMDRF) in the guidance document GHTF/SG1/N77:20121.
|
Seite 4
|
MDCG 2021-24
Guidance on classification of medical devices
|
Practical relevance of classification
|
2
|
The purpose of this chapter is to provide a general overview on the impact of the classification of medical devices on different aspects of the
device compliance with the legal requirements. The explanations provide some simplified concepts and are not exhaustive. For details see the
MDR and related additional guidance2.
|
Seite 4
|
MDCG 2021-24
Guidance on classification of medical devices
|
General requirements
|
2.1
|
Irrespective of the class of the device, all devices must comply with all relevant obligations of the MDR. However, some requirements depend
on the device classification.
For example, the devices must:
- meet the general safety and performance requirements, including the requirements regarding the information to be supplied by the
manufacturer (Annex I of the MDR);
- be subject to the reporting requirements under the medical device vigilance system;
- be CE marked (except custom-made devices and devices intended for clinical investigation, in which case they should comply with the
provisions of respectively Art. 52.8 and Annex XIII or Articles 62 – 80, 82 and Annex XV);
- be assigned a Unique Device Identifier (UDI) number and be registered in the electronic system, in accordance with MDR Article 29;
- if the device is implantable, be supplied with an implant card and information to the patient in accordance with Article 18.According to MDR Article 51 devices are divided into the following classes I, IIa, IIb and III, taking into account the intended purpose of the devices
and their inherent risks. Classification is to be carried out in accordance with Annex VIII to the MDR. In addition, and according to Article 52(7)(a),
(b) and (c), Class I devices can be further subdivided into Is – sterile condition, Im – measuring function and Ir – reusable surgical.
The technical documentation3 to be drawn up by the manufacturer must include the risk class of the device and the justification for the
classification rule(s) applied in accordance with Annex VIII of the MDR.
Sections 2.2-2.6 give an overview of some requirements that depend on the class of the device. For detailed and exhaustive provisions on each
topic, refer to the MDR, as well as to dedicated guidance where available4.
Annex XVI products should be classified in accordance with the classification rules in Annex VIII of the MDR and taking into account possible
provisions within the relevant implementing acts covering Annex XVI devices.
|
Seite 4-5
|
MDCG 2021-24
Guidance on classification of medical devices
|
Conformity assessment
|
2.2
|
Conformity assessment is the process demonstrating whether the requirements of the MDR relating to a device have been fulfilled.
Demonstrating conformity is in the first instance the responsibility of the manufacturer and for most devices classes the conformity is then
assessed by a notified body. The higher the class of the device, the greater the involvement of a notified body in conformity assessment. Annex
I (general safety and performance requirements) and Annexes II (technical documentation) and III (technical documentation on post-market
surveillance) apply to all devices regardless of class. Further relevant conformity assessment procedures (laid down in Annexes IX to XI) will
depend on the class of the device. For some classes, the manufacturer has a choice of more than one procedure. Conformity assessment is
described in MDR Article 52.
Custom-made or investigational devices falling into any class have their own provisions: Annex XIII for custom-made devices and Article 82 for
investigational devices. For class III implantable custom-made devices, the manufacturer also needs to apply either Chapter I of Annex IX or
Part A of Annex XI.
|
Seite 5
|
MDCG 2021-24
Guidance on classification of medical devices
|
Clinical evaluation and investigation
|
2.3
|
For any device regardless of class, the manufacturer must ensure the general safety and performance requirements are satisfied (MDR Article
5, MDR Annex I). This includes carrying out a clinical evaluation (MDR Article 5 (3), MDR Article 61, MDR Annex XIV. For implantable devices
and class III devices, a premarket clinical investigation is compulsory, with some exceptions such as modifications of an existing device,
demonstrated equivalence to CE-marked device, placed on the market under Directive 90/385/EEC or Directive 93/42/EEC for which sufficient
clinical data is already available, and specific exemptions laid down in Article 61(6)(b). The conditions for starting a clinical investigation vary depending on the class of the device (see MDR Article 70(7) and Article 78). According to Article 61(10), if demonstration of conformity with
Annex I requirements based on clinical data is not deemed appropriate, the manufacturer shall justify this in the technical documentation.
For class III implantable devices and class IIb active devices intended to administer or remove a medicinal product, the notified body must also
follow the clinical evaluation consultation procedure where certain documentation including the clinical evaluation report is submitted for review
by expert panels (MDR Article 54 and Section 5.1 of Annex IX). It must notify the Member State competent authorities of the certificates it has
granted for these types of devices (MDR Article 55). The manufacturer may consult an expert panel on their clinical development strategy prior
to performing the clinical evaluation and/or investigation (MDR Article 61(2)). See also MDCG Guideline 2019-35 for interpretation of Article 54.
For implantable devices and class III devices, other than custom-made or investigational devices, the manufacturer must update the post-
market clinical follow-up evaluation report as it will serve an input for the writing of the Periodic Safety Update Report, and, if indicated, the
summary of safety and clinical performance6 (MDR Article 32).
|
Seite 5-6
|
MDCG 2021-24
Guidance on classification of medical devices
|
Post-market surveillance
|
2.4
|
The manufacturer must update the clinical evaluation with clinically relevant information coming from post-market surveillance, in particular
the post-market clinical follow-up.
For class I devices, including sterile, those with a measuring function and the reusable surgical instruments, the manufacturer must prepare
and maintain a post-market surveillance report (MDR Article 85), which must be made available to the competent authorities on request.
For class IIa, IIb and III devices, the manufacturer must prepare a periodic safety update report for each device, and, where relevant, for each
category or group of devices (MDR Article 86). This report must be updated at least annually for class IIb and III devices and at least every two
years for class IIa devices.
|
Seite 6
|
MDCG 2021-24
Guidance on classification of medical devices
|
Traceability
|
2.5
|
For class III implantable devices, economic operators and health institutions are obliged to have a record of the UDI of the devices they have
supplied or with which they have been supplied (MDR Article 27).
For class II and III devices, the economic operator is obliged to provide information on the Member State(s) where the device is, or is to be,
made available when registering the device (Annex VI Part A 2.4). In the case of implantable and class III devices, the economic operator must
provide the summary of safety and clinical performance (Annex VI Part A 2.14). For single-use class I and IIa devices packaged and labelled
individually, the UDI carrier does not have to appear on the packaging but must appear on a higher level of packaging (Annex VI Part C 4.3). However, if the healthcare provider does not have access to the higher level of packaging, the UDI carrier must appear on the individual device
Packaging
|
Seite 6-7
|
MDCG 2021-24
Guidance on classification of medical devices
|
Instructions for use
|
2.6
|
Generally, instructions for use must be supplied together with the device. By way of exception, class I and IIa devices may be supplied without
instructions for use if such devices can safely be used without the instructions and no other provisions of Annex I Section 23 state otherwise.
|
Seite 7
|
MDCG 2021-24
Guidance on classification of medical devices
|
How to carry out classification
|
3
|
This section is aimed at presenting definitions and terms useful for the application of the classification principles and rules.
|
Seite 7
|
MDCG 2021-24
Guidance on classification of medical devices
|
Basic terms and definitions
|
3.1
|
Relevant definitions in respect to the classification of devices are set out in Article 2 and Chapter I of Annex VIII of the MDR but the Regulation
also contains explanation of further terms. These relevant terms and definitions for this guidance are collected below.
|
Seite 7
|
MDCG 2021-24
Guidance on classification of medical devices
|
Specific medical purpose
|
3.1.1.
|
The specific medical purpose is specified by the manufacturer from those listed in the indents of Article 2(1) MDR
|
Seite 7
|
MDCG 2021-24
Guidance on classification of medical devices
|
Duration of use
|
3.1.2.
|
Transient: Normally intended for continuous use for less than 60 minutes.
Short term: Normally intended for continuous use for between 60 minutes and 30 days.
Long term: Normally intended for continuous use for more than 30 days
In certain instances the duration of use for a product needs to be considered as the duration of effect. For instance, application of a topical
cream to the skin may only take seconds to apply but the cream may remain in situ for many hours. The duration of use should therefore not
be considered as the time taken to apply the product but rather the duration for which the product remains in or on the body.
|
Seite 7-8
|
MDCG 2021-24
Guidance on classification of medical devices
|
Continuous use
|
3.1.3.
|
In calculating the duration referred to in Section 1 of Chapter I of Annex VIII of MDR, continuous use means:
‘(a) The entire duration of use of the same device without regard to temporary interruption of use during a procedure or temporary removal for
purposes such as cleaning or disinfection of the device. Whether the interruption of use or the removal is temporary shall be established in
relation to the duration of the use prior to and after the period when the use is interrupted or the device removed; and
(b) the accumulated use of a device that is intended by the manufacturer to be replaced immediately with another of the same type.’
For example, a scalpel may be used on the same patient throughout an operation that may last for several hours. The uninterrupted use for an
intended purpose, i.e. cutting tissue, will normally not last for more than a few seconds at a time. Therefore a scalpel is a transient use device.
However, where usage of a device is discontinued in order for the device to be replaced immediately by the same or an identical device (e.g.
replacement of a ureteric catheter) this shall be considered an extension of the continuous use of the device.
As another example, the overnight period when contact lenses are cleaned and disinfected is considered as a discontinuation of the device use.
For the determination of the duration of use, only the specified time period of uninterrupted wear of the lens (e.g. 16 hours) needs to be taken
into account7.
If it cannot be demonstrated that components of the device are totally discontinued in the interval between uses, this is also considered as an
immediate replacement and an extension of the continuous use of the device.
|
Seite 8
|
MDCG 2021-24
Guidance on classification of medical devices
|
Invasiveness
|
3.1.4.
|
Invasive device
Any device which, in whole or in part, penetrates inside the body, either through a body orifice or through the surface of the body. A device
that administers energy to the body should not be considered as invasive if only energy it emits penetrates the body and not the device itself.
Body orifice
Any natural opening in the body, as well as the external surface of the eyeball, or any permanent artificial opening, such as a stoma
Injured skin or mucous membrane
An area of skin or a mucous membrane presenting a pathological change or change following disease, a wound or a scar.
Surgically invasive device
An invasive device which penetrates inside the body through the surface of the body, including through mucous membranes of body orifices
with the aid or in the context of a surgical operation; and a device which produces penetration other than through a body orifice.
The term surgical operation used in this definition includes all clinical interventional procedures in which a device is placed into the body through
the surface of the body. A surgically invasive device always implies that it enters through an artificially created opening. This can be a large
opening, such as a surgical incision, or it can be a pinprick opening made by a needle. Therefore surgical gloves and needles used with syringes
are surgically invasive.
In this context the following should be noted:
- a surgically created stoma used in urostomy, colostomy and ileostomy or permanent tracheostomy is considered to be a body orifice;
therefore devices introduced into such a stoma are not surgically invasive.
- in contrast, a surgically created opening to allow access to the circulatory system should not be considered to be a body orifice. Devices
introduced into such an opening are surgically invasive.
The concept of surgically invasive should be understood to cover also liquids that are in invasive contact with organs, tissues or other parts of
the body if the access for such liquids is through a surgically created opening.
For a device that administers a substance, such a substance must be assessed in its own right (e.g. substances administered by a jet injector).
Reusable surgical instrument
An instrument intended for surgical use in cutting, drilling, sawing, scratching, scraping, clamping, retracting, clipping or similar procedures,
without a connection to an active device and which is intended by the manufacturer to be reused after appropriate procedures such as cleaning,
disinfection and sterilisation have been carried out.
Implantable device
Any device, including those that are partially or wholly absorbed, which is intended:
— to be totally introduced into the human body, or
— to replace an epithelial surface or the surface of the eye, by clinical intervention and which is intended to remain in place after the procedure.
Any device intended to be partially introduced into the human body by clinical intervention and intended to remain in place after the procedure
for at least 30 days shall also be deemed to be an implantable device.
A ‘procedure’ must be understood in this context to include the surgical procedure during which the implant is placed into the body and the
immediate post-operative care that is associated with the procedure. The ‘procedure’ does not extend to the conclusion of the therapeutic
treatment, e.g. the removal of an implant must be considered to be another ‘procedure’. Thus a plate used to fix a fractured bone and which
remains in place after the procedure for at least 30 days is an implant even if it is taken out after the fracture has healed. In this case the
placing of the plate and its explantation are two different surgical procedures.
Sometimes partially implanted devices are deemed to be implants. For instance, if an operation is carried out specifically to place an infusion
port into the body which would remain in place for at least 30 days after the procedure, such an infusion port would be an implant. However, a
non-tunnelled central venous catheter which is intended for use for temporary vascular access and intended to be removed after 7 – 10 days
is not an implantable device. Nor would a suture used for skin wound closure that is intended to be taken out prior to 30 days be considered an
Implant.
Critical anatomical locations
For the purposes of the MDR, ‘Central circulatory system’12 means the following blood vessels:
arteriae pulmonales, aorta ascendens, arcus aortae, aorta descendens to the bifurcatio aortae, arteriae coronariae, arteria carotis communis,
arteria carotis externa, arteria carotis interna, arteriae cerebrales, truncus brachiocephalicus, venae cordis, venae pulmonales, vena cava
superior and vena cava inferior.
For the purposes of the MDR, ‘Central nervous system’13 means the brain, meninges and spinal cord.
|
Seite 8-10
|
MDCG 2021-24
Guidance on classification of medical devices
|
Active medical devices
|
3.1.5.
|
Active device means any device, the operation of which depends on a source of energy other than that generated by the human body for that
purpose, or by gravity, and which acts by changing the density of or converting that energy. Devices intended to transmit energy, substances
or other elements between an active device and the patient, without any significant change, shall not be deemed to be active devices.
The concept act by converting energy includes conversion of energy in the device and/or conversion at the interface between the device and
the tissues or in the tissues. Electrodes intended for E.C.G. or E.E.G are normally not considered active devices because they do not normally
act by conversion of energy.
|
Seite 10-11
|
MDCG 2021-24
Guidance on classification of medical devices
|
Devices with a measuring function
|
3.1.6.
|
The following criteria, if fulfilled together, indicate that a device has a measuring function:
a) The device is intended by the manufacturer to measure:
- quantitatively a physiological or anatomical parameter, or
- a quantity or a quantifiable characteristic of energy or of substances (including medicinal products) delivered to or removed from the human
body. Spoons or plastic syringes co-packed with medicinal products and used to measure a quantity of that medicinal product to be administered
to the patient are in this category. Devices for the delivery of liquid to the human body without graduation or scale (e.g. medicine spoons, cups,
droppers without graduation or scale or display of measuring unit) are not in this category.
b) The result of the measurement:
- is displayed in legal units or other acceptable units within the meaning of Directive 80/181/ECC20, or
- is compared to at least one point of reference indicated in legal units or other acceptable units in compliance with the mentioned directive..
c) The intended purpose implies accuracy, claimed explicitly or implicitly, where a non-compliance with the implied accuracy could result in a
significant adverse effect on the patient’s health and safety.
The expression ‘claimed implicitly’ covers cases where the user, on the basis of the designation of the device or of its accompanying documents,
or on the basis of the common use, is entitled to expect accuracy where the accuracy of the measurement has an impact on the diagnosis or
therapy of the patient.
Measuring activities during the manufacturing process including those for calibration purposes are not covered and do not imply a measuring
function of the manufactured device.
|
Seite 12
|
MDCG 2021-24
Guidance on classification of medical devices
|
Systems and procedure packs
|
3.1.7.
|
System and procedure packs is described in MDR Article 22. They can combine medical devices, in vitro diagnostic medical devices, and other
products which are in conformity with legislation that applies to those products, only where they are used within a medical procedure or their
presence in the system or procedure pack is otherwise justified. In this case of demonstrated legal conformity of each component, the systems
or procedure packs no not need to bear themselves an additional CE marking but they must bear the name, registered trade name or registered
trade mark of the person who combines the products as well as the address at which that person can be contacted.
A procedure pack means a combination of products packaged together and placed on the market with the purpose of being used for a specific
medical purpose21. A system means a combination of products, either packaged together or not, which are intended to be interconnected or
combined to achieve a specific medical purpose.
Where the system or procedure pack incorporates devices which do not bear the CE marking or where the chosen combination of devices is not
compatible in view of their original intended purpose, or where the sterilisation has not been carried out in accordance with the manufacturer's
instructions the system or procedure pack shall be treated as a device in its own right and shall be subject to the relevant conformity assessment
procedure pursuant to MDR Article 52. The classification is determined by the intended use of the system or procedure pack. The natural or
legal person that combines the devices must assume the obligations incumbent on manufacturers.
For such combinations, including different devices, the classification is normally determined by the intended use. In those cases where the
intended use of the final device is not specific enough to determine the classification, the classification of the device is at the level of the highest
classified device included, taking into account the new intended use of the device.
|
Seite 12-13
|
MDCG 2021-24
Guidance on classification of medical devices
|
Other terms
|
3.1.8.
|
This section gives notes on other terms used in Annex VIII of the MDR:
Systemic absorption: The process by which substances or their metabolites enter the body (e.g. by crossing mucous membranes) and are
distributed into the body via the blood and/or lymphatic system.
Wholly or mainly absorbed: The term ‘absorption’ in the context of implantable devices refers to the degradation of a material within the
body and the metabolic elimination of the resulting degradation products from the body. It does not apply to those substances that are excreted
without modification from the body, e.g. insufflation gases for the abdominal cavity or laparoscopic and endoscopic procedures.
Local dispersion: The condition by which substances remain in a specific site without being distributed into the body via the blood and/or
lymphatic system.
Medicine / medicinal product: According to the definition given in Directive 2001/83/EC:
‘(a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or
(b) Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring,
correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical
Diagnosis.’
A ‘nanomaterial’ means a natural, incidental or manufactured material containing particles in an unbound state or as an aggregate or as an
agglomerate and where, for 50% or more of the particles in the number size distribution, one or more external dimensions is in the size range
1-100 nm; Fullerenes, graphene flakes and single-wall carbon nanotubes with one or more external dimensions below 1 nm shall also be deemed
to be nanomaterials according to MDR, Article 2(18). Related definitions on ‘particle’, ‘agglomerate’ and ‘aggregate’ are also included in the
MDR Article 2(19-21). The definitions on nanomaterial and the related terms were taken from Commission Recommendation 2011/696/EU on
the definition of nanomaterials23. Guidance on terms and concepts used in the definition can be found in a report from the European
Commission’s Joint Research Centre.
Derivative means a non-cellular substance extracted from human or animal tissue or cells through a manufacturing process. The final substance
used for manufacturing of the device in this case does not contain any cells or tissues.
|
Seite 13-14
|
MDCG 2021-24
Guidance on classification of medical devices
|
Application of the classification rules
|
3.2
|
Before applying the classification rules, the manufacturer should first determine if the product concerned, based on its specific medical purpose,
falls in the scope of the MDR as medical device, accessory for a medical device (Article 2 MDR), medical device part or component for replacement
(Article 23(2) MDR) or as a device without an intended medical purpose listed in Annex XVI.
It is the intended and not the accidental use of the device that determines the class of the device. For instance, a suture organiser that is
intended to keep suture threads used in open heart surgery in the correct order should not be considered as an invasive device if it is intended
to be kept outside the patient. Similarly, if a healthcare professional or others uses the device in a manner not intended by the manufacturer,
this does not change the class of the device for the purpose of conformity assessment. However, if the normal clinical use of the device changes
in time with evolving clinical practice such that the intended purpose and classification of the device changes, this should be addressed by the
manufacturer and the conformity of the device assessed for the new intended purpose. It is the intended purpose assigned by the manufacturer
to the device that determines the class of the device and not the class assigned to other similar products. For instance, two sutures that have
the same composition may well have different intended purposes.
In case several rules, or if, within the same classification rule, several sub-rules, apply to the same device based on the device intended purpose,
the strictest rule and sub-rule resulting in higher classification will apply.
In terms of further clarification of the classification rules, the elements listed below should also be considered.
|
Seite 14
|
MDCG 2021-24
Guidance on classification of medical devices
|
How to use the rules
|
3.2.1.
|
The manufacturer must take into consideration all the rules in order to establish the proper classification for its device. The strictest rule and
sub-rule resulting in the highest classification determines the class25. It is quite conceivable for instance that one of the general rules that is
not specific to active devices nevertheless applies to such a device. The intended purpose and all the device characteristics must be taken into
consideration. The characteristic or combination of characteristics in accordance with the intended purpose of the device that falls into the
highest class determines the class for the device as a whole.
In addition to the classification rules set out in Annex VIII of MDR, the manufacturers must also take account of any applicable legal acts and
consider guidance documents which may support the classification of their device.
|
Seite 15
|
MDCG 2021-24
Guidance on classification of medical devices
|
Practical example
|
3.2.2.
|
A simple wound drainage system has usually three components that must be taken into consideration: the cannula, the tubing and the collector
unit. If the system is sold without a cannula, then the classification of the cannula does not need to be taken into account. It is assumed here
that the system is used for short term duration, i.e. that uninterrupted intended use is more than 60 minutes and less than 30 days. It is
furthermore assumed that the collected liquids are not intended to be reinfused into the body nor reprocessed for eventual reinfusion and that
the device is not intended to be connected to a powered suction system.
Intended uses: Surgically invasive cannula to reach a wound site in the pleural cavity to drain the cavity, Rule: 7, Class: IIa
Intended uses: Non-invasive tubing to evacuate body liquids towards the collector.,Rule: 1, Class: I
Intended uses: Non-invasive collector to receive the body liquids.,Rule: 1, Class: I
The clear conclusion here is that the manufacturer would have a choice of applying class IIa to the whole device or carrying out separate
conformity assessment procedures for the cannula on one hand and the tubing and collector on the other hand
|
Seite 15
|
MDCG 2021-24
Guidance on classification of medical devices
|
Handling of interpretational problems
|
3.3
|
It is recognised that although the existing rules will adequately classify the vast majority of existing devices, a small number of devices may be
more difficult to classify.
As soon a notified body needs to be involved, any dispute between the manufacturer and the notified body concerned, arising from the
application of Annex VIII, may be referred for a decision to the competent authority of the Member State in which the manufacturer (or its
authorized representative) has its registered place of business. In cases where the manufacturer has no registered place of business in the
Union and has not yet designated an authorised representative, the matter shall be referred to the competent authority of the Member State in
which the authorised representative referred to in the last indent of point (b) of the second paragraph of Section 2.2 of Annex IX has its
registered place of business. Where the notified body concerned is established in a Member State other than that of the manufacturer, the
competent authority must adopt its decision after consultation with the competent authority of the Member State that designated the notified
body. The competent authority of the Member State in which the manufacturer has its registered place of business will notify the MDCG and
the Commission of its decision. The decision can be made available upon request26.
Outside this regulatory procedure, competent authorities may refer on an ad hoc and voluntary basis complex classification cases for discussion
at the Borderline and Classification Working Group of the MDCG. Agreement positions on classification reached by this Working Group are
published for reference in the Manual on Borderline and Classification.
|
Seite 15
|
MDCG 2021-24
Guidance on classification of medical devices
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.